BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
3.870
-0.040 (-1.02%)
At close: Oct 12, 2026, 4:00 PM EDT
3.820
-0.050 (-1.29%)
Pre-market: Oct 13, 2026, 6:45 AM EDT
BriaCell Therapeutics Employees
BriaCell Therapeutics had 16 employees as of July 31, 2023. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change
10
Growth
166.67%
Revenue / Employee
n/a
Profits / Employee
-$1,917,204
Market Cap
34.21M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jul 31, 2023 | 16 | 10 | 166.67% | 16 | 0 |
| Jul 31, 2021 | 6 | 0 | - | 5 | 1 |
| Aug 1, 2019 | 6 | - | - | 5 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 113 |
| Aligos Therapeutics | 82 |
| NextCure | 40 |
| Actinium Pharmaceuticals | 27 |
| Filana Therapeutics | 20 |
| CervoMed | 15 |
| NanoViricides | 7 |
| Lite Strategy | 5 |
BCTX News
- 6 days ago - BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting - GlobeNewsWire
- 4 weeks ago - BriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Market's Cautious Outlook - GuruFocus
- 4 weeks ago - BriaCell announces DSMB recommendation to continue Bria-ABC study - TheFly
- 4 weeks ago - Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study - GlobeNewsWire
- 4 weeks ago - BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center - GlobeNewsWire
- 7 weeks ago - BriaCell (BCTX) Advances Melanoma Vaccine Development Amid Challenging Valuation Metrics - GuruFocus
- 7 weeks ago - BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+ - TheFly
- 7 weeks ago - BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ - GlobeNewsWire